Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018.
Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018.
复制标题
DOI：
10.1016/j.jpain.2022.01.006
复制
发表时间：
2022-07
期刊：
影响因子：
4
通讯作者：
Olfson, Mark
中科院分区：
文献类型：
--
作者：
Gorfinkel, Lauren R.;Hasin, Deborah;Saxon, Andrew J.;Wall, Melanie;Martins, Silvia S.;Cerda, Magdalena;Keyes, Katherine;Fink, David S.;Keyhani, Salomeh;Maynard, Charles C.;Olfson, Mark
As opioid prescribing has declined, it is unclear how the landscape of prescription pain treatment across the U.S. has changed. We used nationally-representative data from the Medical Expenditure Health Survey, 2014 to 2018 to examine trends in prescriptions for opioid and non-opioid pain medications, including acetaminophen, non-steroidal anti-inflammatory drugs, gabapentinoids, and antidepressants among U.S. adults with self-reported pain. Overall, from 2014 to 2018, the percentage of participants receiving a prescription for opioids declined, (38.8% vs 32.8%), remained stable for non-steroidal anti-inflammatory drugs (26.8% vs 27.7%), and increased for acetaminophen (1.6% vs 2.3%), antidepressants (9.6% vs 12.0%) and gabapentinoids (13.2% vs 19.0%). In this period, the adjusted odds of receiving an opioid prescription decreased (aOR = .93, 95% CI = .90–.96), while the adjusted odds of receiving antidepressant, gabapentinoid and acetaminophen prescriptions increased (antidepressants: aOR = 1.08, 95% CI = 1.03–1.13 gabapentinoids: aOR = 1.11, 95% CI = 1.06–1.17; acetaminophen: aOR = 1.10, 95% CI: 1.02–1.20). Secondary analyses stratifiying within the 2014 to 2016 and 2016 to 2018 periods revealed particular increases in prescriptions for gabapentinoids (aOR = 1.13, 95% CI = 1.05–1.21) and antidepressants (aOR = 1.23, 95% CI = 1.12–1.35) since 2016. These data demonstrate that physicians are increasingly turning to CDC-recommended non-opioid medications for pain management, particularly antidepressants and gabapentinoids. However, evidence for these medications’ efficacy in treating numerous common pain conditions, including low back pain, remains limited.
登录
查看更多内容
DOI：
10.1136/bmj.m4825
发表时间：
2021-01-20
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Ferreira GE;McLachlan AJ;Lin CC;Zadro JR;Abdel-Shaheed C;O'Keeffe M;Maher CG
通讯作者：
Maher CG
影响因子：
3.5
作者：
Bastiaens, Leo;Galus, James;Mazur, Cherise
通讯作者：
Mazur, Cherise
影响因子：
3.1
作者：
Dasgupta, Nabarun;Funk, Michele Jonsson;Marshall, Steve
通讯作者：
Marshall, Steve
影响因子：
14.6
作者：
Enke, Oliver;New, Heather A.;Lin, C. -W. Christine
通讯作者：
Lin, C. -W. Christine
影响因子：
5.1
作者：
Attal, N.;Cruccu, G.;Nurmikko, T.
通讯作者：
Nurmikko, T.